Company profile: MOMA Therapeutics
1.1 - Company Overview
Company description
- Provider of precision-medicine drug discovery targeting molecular machines involved in disease, enabled by a biomechanics engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. Advancing precision oncology programs toward clinical trials and collaborating with Roche on a five-year effort to identify critical cancer dependencies.
Products and services
- Biomechanics Engine: A multi-disciplinary engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics to advance drug discovery
- Drug Discovery Platform: A precision-medicine platform engineered to discover precision medicines by targeting molecular machines involved in diseases, with applications in precision oncology
- Precision Oncology Programs: Clinical-trial-directed programs at MOMA Therapeutics advancing multiple precision oncology efforts towards clinical trials in cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MOMA Therapeutics
Forbius
HQ: United States
Website
- Description: Provider of clinical-stage biotherapeutics for the treatment of cancer and fibrotic diseases, developing agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forbius company profile →
Cabrellis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical cancer therapy development, planning three small cell lung cancer clinical trials in 2006, including a study assessing the safety and efficacy of Calsed(TM) in reference to topotecan for second-line treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cabrellis company profile →
Bolt Biotherapeutics
HQ: United States
Website
- Description: Provider of a biotechnology platform for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bolt Biotherapeutics company profile →
Dendreon
HQ: United States
Website
- Description: Provider of immunotherapy and cell therapy services, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for advanced prostate cancer; end-to-end cell therapy manufacturing; patient operations and logistics to deliver treatments within an 18-hour window across the U.S.; process and analytical development; and cGMP quality assurance and quality control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dendreon company profile →
Biomea Fusion
HQ: United States
Website
- Description: Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomea Fusion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MOMA Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MOMA Therapeutics
2.2 - Growth funds investing in similar companies to MOMA Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MOMA Therapeutics
4.2 - Public trading comparable groups for MOMA Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →